NCT02273570 - Optimal Anemia Treatment in End Stage Renal Disease (ERSD) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 31, 2015

Primary Completion Date

December 31, 2016

Study Completion Date

March 31, 2017

Conditions

Hyperparathyroidism, Secondary

Interventions

DRUG

standard care

Standard care. Patients allocated to this study arm will be treated with all drugs available for PTH control (at the investigator discretion) to obtain a iPTH of 300-540 pg/ml.

DRUG

Optimal (I. iPTH control: Zemplar®,Mimpara®; phosphorous control: Renvela®, Phoslo®, Osvaren®, Foznol®,Maalox®; calcium control: calcium and vitamin D

Optimal care. Patients allocated to this study arm will be treated with all drugs available for PTH control (at the investigator discretion - see therapeutic algorithm) to obtain a iPTH of less than 300 pg/ml.

Trial Locations (1)

22020

RECRUITING

Azienda Ospedaliera Sant'Anna, San Fermo Della Battaglia (CO)